Erlotinib Completed Phase 0 Trials for Head and Neck Carcinoma / Pharynx Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment0
clinicaltrials.gov IdentifierTitleDrugs
NCT00601913Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
NCT00140556Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer